首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations
【24h】

Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations

机译:Agomelatine 25 mg片剂在健康中国受试者中的生物等效性和药代动力学特征:四向重复交叉研究表明个体间和个体间差异很大

获取原文
           

摘要

The present study was designed to assess the bioequivalence of two agomelatine formulations (25-mg tablets) in healthy Chinese male subjects. This single-dose, open-label, randomized, four-way replicate study with a 1-week washout period was conducted in 60 healthy Chinese male volunteers under fasting conditions. Blood samples were collected over a 12-h period after a single dose of the 25-mg agomelatine test (T) formulation or a reference (R) formulation, and the drug concentrations were assayed by liquid chromatography tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were calculated using a non-compartmental model. Bioequivalence between the formulations was assessed. Tolerability and safety were monitored by physical examination, electrocardiogram (12-lead ECG), clinical laboratory tests, and adverse events (AEs). A total of 56 out of 60 subjects completed the study. No AEs were observed. The values of maximum plasma concentration ( C max), maximum concentration ( T max), area under curve ( AUC )0– t and t 1/2 were 12.032?ng/mL, 0.658?h, 12.637?ng·h/mL, and 0.813?h, respectively, for the test formulation, and 10.891?ng/mL, 0.709?h, 11.572?ng·h/mL, and 0.96?h, respectively, for the reference formulation. The intra-individual variability of C max and AUC 0? t were 78.3 and 61.8%, respectively. The inter-individual coefficients of variance (CVs) of C max and AUC 0? t were approximately 100%. The 90% confidence intervals for the ratio of means for the log-transformed C max (97.7–124.9%), AUC 0? t (98.2–118%), and AUC 0?∞ (97.8–117.2%) were within the guideline range of bioequivalence (80–125%). The test and reference formulations of agomelatine met the regulatory criteria for bioequivalence of the Chinese Food and Drug Administration. Significant intra-individual and inter-individual variations were found.
机译:本研究旨在评估在健康的中国男性受试者中两种阿戈美拉汀制剂(25毫克片剂)的生物等效性。这项单剂量,开放标签,随机,四次重复研究,为期1周,在禁食条件下在60名健康的中国男性志愿者中进行。在单剂25 mg阿戈美拉汀试验(T)制剂或参比(R)制剂单次给药后的12小时内采集血样,并通过液相色谱串联质谱法(LC-MS /多发性硬化症)。使用非房室模型计算药代动力学参数。评估制剂之间的生物等效性。通过体格检查,心电图(12导联心电图),临床实验室测试和不良事件(AE)监测耐受性和安全性。 60名受试者中共有56名完成了研究。没有观察到AE。最大血浆浓度(C max ),最大浓度(T max ),曲线下面积(AUC) 0–t 和t的值测试配方的 1/2 分别为12.032?ng / mL,0.658?h,12.637?ng·h / mL和0.813?h,以及10.891?ng / mL,0.709?参考配方的h,11.572?ng·h / mL和0.96?h。 C max 和AUC 0的个体内变异性? t 分别为78.3和61.8%。 C max 和AUC 0的个体间方差系数(CV)? t 大约为100%。对数转换后的C max 的均值比(97.7–124.9%)的90%置信区间,AUC 0? t (98.2–118%)和AUC 0?∞(97.8–117.2%)在生物等效性的指导范围内(80–125%)。阿戈美拉汀的测试和参考配方符合中国食品药品监督管理局的生物等效性监管标准。发现个体间和个体间存在显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号